Newsroom

AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013

April 19, 2013 | Investor News, Press Releases

LEXINGTON, Mass.–(BUSINESS WIRE)–Apr. 19, 2013–
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report
unaudited consolidated financial results for the quarter ended March 31,
2013 after the U.S. financial markets close on Tuesday, April 23, 2013.
The announcement will be followed by a conference call and webcast with
slides at 4:30 p.m. ET during which management will provide a business
update and review first quarter financial results.

To access the conference call via telephone, please dial (877) 412-6083
from the United States or (702) 495-1202 for international access. A
telephone replay will be available from approximately 7:30 p.m. ET on
April 23, 2013 through midnight April 30, 2013. To access a replay of
the conference call, dial (855) 859-2056 from the United States or (404)
537-3406 for international access. The pass code for the live call and
the replay is 37544923.

The call will be webcast with slides and accessible through the
Investors section of the company’s website at www.amagpharma.com.
The webcast replay will be available from approximately 7:30 p.m.
ET on April 23, 2013 through midnight May 23, 2013.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that
manufactures and markets Feraheme® (ferumoxytol) Injection for
Intravenous (IV) use in the United States. Along with driving organic
growth of its lead product, AMAG intends to expand its portfolio with
additional commercial-stage specialty pharmaceuticals. The company is
seeking complementary products that leverage the company’s commercial
footprint and focus on hematology and oncology centers and hospital
infusion centers. For additional company information, please visit www.amagpharma.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303